Brisbane, Australia-based oral appliance marketer Oventus Medical Ltd has signed lab-in-lab agreements across 9 sites with two new sleep groups, Tri Hospital Sleep and Ontario Sleep Care, both located in Canada.
Under these agreements, Oventus technology will be offered to patients of the 9 sites.
Chris Hart, M.Phil, BSc, BDSc, founder CEO of Oventus, says in a release, “These businesses have been delivering high quality respiratory care for many years, even decades. Oventus is proud that such well-respected sleep groups in North America have chosen to strengthen their existing sleep offering by adopting our treatment platform. As COVID-19 restrictions start to lift, we expect to see patient flow slowly increasing across our existing sites and the new sites we have been working hard through the recent shutdowns to bring online.”
Tri Hospital Sleep Agreement
Tri Hospital Sleep in Ontario is one of Mississauga’s largest privately-owned providers of diagnostics and treatment for OSA. Under the agreement, lab-in-lab facilities will be implemented in its largest location with 14 beds of sleep diagnostics.
Tri Hospital medical director Mohamad Hussain, MD, says in a release, “We are excited to bring a dental-sleep collaborative care model into our sleep center. This is something we have been thinking about for quite some time. We realize CPAP isn’t for everyone and now we can provide our patients with the option to use an oral appliance.”
The agreement has a term of three years, with an automatic three-year renewal, unless a party elects not to renew no later than 180 days prior to the end of the third year. Oventus expects to see the lab-in-lab program deployed in August with minimum monthly quotas, in line with other agreements, at 20 devices per month once fully operational.
Ontario Sleep Care agreement
Ontario Sleep Care is a large, privately-owned provider of treatment for OSA with 8 locations across the province of Ontario, Canada. The agreement provides Oventus’ O2Vent Optima and ExVent therapy across the network of sites as an alternative for CPAP-intolerant individuals. Patients will also be referred to the 8 sites from satellite locations.
Scott Reynolds, director of operations for Ontario Sleep Care, says in a release, “The Oventus offering will enable us to provide a valued option for patients to treat their apnea and will allow us to overcome treatment objections due to CPAP masks.”
Once fully deployed, each Ontario Sleep Care location expects to order 10 O2Vent Optima devices per month. The agreement has a term of three years, with an automatic three-year renewal, unless a party elects not to renew no later than 180 days prior to the end of the third year.